Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate

Eur Urol. 1991;19(3):192-5. doi: 10.1159/000473617.


Twenty-one patients with stage T3 cancer of the prostate underwent complete androgen deprivation (LH-RH agonist and flutamide) for 3 months prior to radical prostatectomy. Two problems were to be dealt with: the decrease in the volume of the prostate, and the possibility of downstaging (= pT less than pT3 according to the UICC 1987 classification) of the prostatic cancer. A decrease in the volume was noted in each case. A downstaging effect (pT in comparison to T stage) was noted in 33% of the patients. The downstaging effect was noted in 75% of grade 1 tumor, in 31% of grade 2 tumors, but not in grade 3 tumors.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Buserelin / analogs & derivatives*
  • Buserelin / therapeutic use
  • Combined Modality Therapy
  • Flutamide / therapeutic use*
  • Gonadotropin-Releasing Hormone / drug effects
  • Goserelin
  • Humans
  • Male
  • Pilot Projects
  • Preoperative Care
  • Prostatectomy
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / surgery
  • Time Factors


  • Goserelin
  • Gonadotropin-Releasing Hormone
  • Flutamide
  • Buserelin